Corticosteroids for treating severe sepsis and septic shock

Cochrane Database of Systematic Reviews

Volumn 2004, Issue 1, 2004, Pages

  Annane, Djillali ^a   Bellissant, Eric ^b   Bollaert, Pierre Edouard ^c   Briegel, Josef ^d   Keh, Didier ^e   Kupfer, Yizhak ^f  

^a RAYMOND POINCARÉ HOSPITAL   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

DEATH; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; METABOLIC DISORDER; METHODOLOGY; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; NEUROMUSCULAR WEAKNESS; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPSIS; SEPTIC SHOCK; SUPERINFECTION; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT DURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MORTALITY; RANDOMIZED CONTROLLED TRIAL;

ADRENAL CORTEX HORMONES; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEPSIS; SHOCK, SEPTIC;

EID: 2942738987     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002243.pub2     Document Type: Review

References (87)

1. Annane D, Sebille V, Charpentier C, Bollaert PE, François B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-71. [PUBMED: 12186604]
2. COIITSS Study Investigators, Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, Timsit JF, et al. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010;303:341-8.
3. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Critical Care Medicine 1998;26(4):645-50. [PUBMED: 9559600]
4. Bone RG, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. New England Journal of Medicine 1987;317(11):653-8.
5. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Critical Care Medicine 1999;27(4):723-32. [PUBMED: 10321661]
6. Chawla K, Kupfer Y, Tessler S. Hydrocortisone reverses refractory septic shock. Critical Care Medicine 1999;27(1):A33.
7. Cicarelli DD, Vieira JE, Benseñor FE. Early dexamethasone treatment for septic shock patients: a prospective randomized clinical trial. Sao Paulo Medical Journal 2007;125:237-41. [PUBMED: 17992396]
8. Confalonieri M, Urbino R, Potena A, Piatella M, Parigi P, Giacomo P, et al. Hydrocortisone infusion for severe community acquired pneumonia: a preliminary randomized study. American Journal of Respiratory and Critical Care Medicine 2005;171:242-8.
9. Cooperative Study Group. The effectiveness of hydrocortisone in the management of severe infections. JAMA 1963;183:462-5.
10. Huh JW, Lim CM, Koh Y, Hong SB. Effect of low doses of hydrocortisone in patient with septic shock and relative adrenal insufficiency: 3 days versus 7 days treatment. Critical Care Medicine 2007;34 Suppl:A101.
11. Keh D, Boehnke T, Weber-Cartens S, Schulz C, Ahlers O, Bercker S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. American Journal of Respiratory and Critical Care Medicine 2003;167(4):512-20. [PUBMED: 12426230]
12. Klastersky J, Cappel R, Debusscher L. Effectiveness of betamethasone in management of severe infections. A double-blind study. New England Journal of Medicine 1971;284(22):1248-50. [PUBMED: 4929896]
13. Lucas C, Ledgerwood A. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Archives of Surgery 1984;119(5):537-41. [PUBMED: 6712466]
14. Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. American Review of Respiratory Diseases 1988;138(1):62-8. [PUBMED: 3202402]
15. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, et al. Methylprednislone infusion in early ARDS: result of a randomised controlled trial. Chest 2007;131(4):954-63. [PUBMED: 17426195]
16. Oppert M, Schindler R, Husung C, Offerman K, Graef KJ, Boenisch O, et al. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Critical Care Medicine 2005;33:2457-64. [PUBMED: 16276166]
17. Rinaldi S, Adembri C, Grechi S, DE Gaudio R. Low-dose hydrocortisone during severe sepsis: effects on microalbumineria. Critical Care Medicine 2006;34:2334-9. [PUBMED: 16850006]
18. Schumer W. Steroids in the treatment of clinical septic shock. Annals of Surgery 1976;184(3):333-41. [PUBMED: 786190]
19. Slusher T, Gbadero D, Howard C, Lewinson L, Giroir B, Toro L, et al. Randomized, placebo-controlled, double blinded trial of dexamethasone in African children with sepsis. Pediatric Infectious Diseases Journal 1996;15(7):579-83. [PUBMED: 8823850]
20. Sprung CL, Caralis PV, Marcial EH, Pierce M, Gelbard MA, Long WM, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. New England Journal of Medicine 1984;311(18):1137-43. [PUBMED: 6384785]
21. Sprung C, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. The CORTICUS randomized, double-blind, placebo-controlled study of hydrocortisone therapy in patients with septic shock. New England Journal of Medicine 2008;358:111-24. [PUBMED: 18184957]
22. Tandan SM, Guleria R, Gupta N. Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India. Proceedings of the American Thoracic Society Meeting. 2005:A24.
23. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. New England Journal of Medicine 1987;317(11):659-65. [PUBMED: 2888017]
24. Wagner HN, Bennett IL, Lasagna L, CluffLE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bulletin of Johns Hopkins Hospital 1955;98:197-215. [PUBMED: 13304518]
25. Yildiz O, Doganay M, Aygen B, Guven M, Keleutimur F, Tutuu A. Physiologic-dose steroid therapy in sepsis. Critical Care 2002;6(3):251-9. [PUBMED: 12133187]
26. Cicarelli DD, Bensenor FEM, Vieira JE. Effects of single dose of dexamethasone on patients with systemic inflammatory response. Sao Paulo Medical Journal 2006;124:90-5. [PUBMED: 16878192]
27. Hahn EO, Houser HB, Rammelkamp CH, Denny FW, Wannamaker LW. Effect of cortisone on acute streptococcal infections and post-streptococcal complications. Journal of Clinical Investigation 1951;30:274-81.
28. Hughes GS Jr. Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. Life Sciences 1984;35(23):2319-26. [PUBMED: 6390057]
29. Kaufmann I, Briegel J, Schliephake F, Hoelzl A, Chouker A, Hummel T, et al. Stress doses of hydrocortisone in septic shock: beneficial effects on opsonization-dependent neutrophil functions. Intensive Care medicine 2008;34:344-9. [PUBMED: 17906853]
30. McKee JI, Finlay WE. Cortisol replacement in severely stressed patients. Lancet 1983;1(8322):484. [PUBMED: 6131207]
31. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280(2):159-65. [PUBMED: 9669790]
32. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yamaguchi H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 2007;185:249-55. [PUBMED: 17710485]
33. Rogers J. Large doses of steroids in septicaemic shock. British Journal of Urology 1970;42(6):742. [PUBMED: 4923652]
34. Thompson WL, Gurley HT, Lutz BA, Jackson DL, Kvols LK, Morris IA. Inefficacy of glucocorticoids in shock (double-blind study). Clinical Research 1976;24:258A.
35. Weigelt JA, Norcross JF, Borman KR, Snyder WH 3rd. Early steroid therapy for respiratory failure. Archives of Surgery 1985;120(5):536-40. [PUBMED: 3885915]
36. Effect of treatment with low-dose hydrocortisone on cirrhotic patients presenting with septic shock to the intensive care unit. Ongoing study 01/04/2004.
37. 6-methylprednisolone for multiple organ dysfunction syndrome. Ongoing study 01/08/2005.
38. Low dose hydrocortisone in acutely burned patients. Ongoing study 01/04/2005.
39. Hydrocortisone versus hydrocortisone plus fludrocortisone for the treatment of adrenal insufficiency in severe sepsis. Ongoing study September 2006.
40. Dexamethasone infusion in community acquired pneumonia. Ongoing study 01/05/2008.
41. Steroids in patients with early ARDS. Ongoing study February 2008.
42. Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHS). Ongoing study April 2008.
43. Hydrocortisone for prevention of septic shock. Ongoing study 01/06/2008.
44. Evaluation of corticosteroid therapy in childhood severe sepsis: a randomized pilot study. Ongoing study 01/04/2008.
45. ACCP/SCCM consensus conference panel. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 1992;20(6):864-74. [PUBMED: 1597042]
46. Annane D, Sébille V, Troché G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283(8):1038-45. [PUBMED: 10697064]
47. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, CUB-Rea Network. Current epidemiology of septic shock: the CUB-Réa Network. American Journal of Respiratory and Critical Care Medicine 2003;168(2):165-72. [PUBMED: 12851245]
48. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78. [PUBMED: 15639681]
49. Annane D. Improving clinical trials in the critically ill: unique challenge: sepsis. Critical Care Medicine 2009;37 Suppl:117-28. [PUBMED: 19104211]
50. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. American Journal of Respiratory and Critical Care Medicine 1995;152 Suppl(6 Pt 2):125-40. [PUBMED: 7489120]
51. Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Annals of Internal Medicine 1991;114(4):332-3. [PUBMED: 1987879]
52. Briegel J, Kellermann W, Forst H, Haller M, Bittl M, Hoffmann GE, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clinical Investigation 1994;72:782-7. [PUBMED: 7865982]
53. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. New England Journal of Medicine 1995;322(20):1351-62. [PUBMED: 7715646]
54. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. New England Journal of Medicine 2003;348(8):727-34. [PUBMED: 12594318]
55. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MAD, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Critical Care Medicine 1995;23(8):1430-9. [PUBMED: 7634816]
56. de Kruif MD, Lemaire LC, Giebelen IA, van Zoelen MA, Pater JM, van den Pangaart PS, et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. Journal of Immunology 2007;178:1845-51. [PUBMED: 17237435]
57. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medicine 2008;36:296-327. [PUBMED: 20035219]
58. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA 2001;285:2000-3. [PUBMED: 11308438]
59. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34. [PUBMED: 9310563]
60. Fabian TC, Patterson R. Steroid therapy in septic shock. Survival studies in a laboratory model. American Surgeon 1982;48(12):614-7. [PUBMED: 6760756]
61. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Medicine 2004;30:589-96. [PUBMED: 14963646]
62. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6. [PUBMED: 18436948]
63. Guyatt GH, Wyer P, Ioannidis J. When to believe a subgroup analysis. In: Guyatt G, Rennie R, Meade M, Cook D editor(s). User's Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice. New York: McGraw-Hill, 2008.
64. Heller AR, Heller SC, Borkenstein A, Stehr SN, Koch T. Modulation of host defense by hydrocortisone in stress doses during endotoxemia. Intensive Care Medicine 2003;29:1456-63. [PUBMED: 12879235 []
65. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library. Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
66. Hotta M, Baird A. Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro. Proceedings of the National Academy of Sciences of the United States of America 1986;83(20):7795-9. [PUBMED: 3020557]
67. Huang ZH, Gao H, Xu RB. Study on glucocorticoid receptors during intestinal ischemia shock and septic shock. Circulatory Shock 1987;23(1):27-36. [PUBMED: 3690811]
68. Ioannidis JPA Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141:781-8.
69. Jaattela M, Ilvesmaki V, Voutilainen R, Stenman UH, Saksela E. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology 1991;128(1):623-9. [PUBMED: 1702707]
70. Juni P, Altman DG, Egger M. Systematic reviews in healthcare: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
71. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Archives of Internal Medicine 2007;168:1468-9. [PUBMED: 17698689]
72. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Critical Care Medicine 1995;23(7):1294-303. [PUBMED: 7600840]
73. Lipiner D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, et al. Adrenal function in sepsis: The restrospective corticus cohort study. Critical Care Medicine 2007;35:1012-8.
74. Loisa P, Parviainen I, Tenhunen J, Hovilehto S, Ruokonen E. Effect of mode of hydrocortisone administration on glycemic control in patients with septic shock: A prospective randomized trial. Critical Care 2007;11:R21. [PUBMED: 17306016]
75. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. New England Journal of Medicine 2003;348:1546-54. [PUBMED: 12700374]
76. Meduri GU, Chrousos GP. Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way?. Chest 1998;114(2):355-60. [PUBMED: 9726712]
77. Molijn GJ, Koper JW, van Uffelen CJ, de Jong FH, Brinkmann AO, Bruining HA, et al. Temperature-induced down-regulation of the glucocorticoid receptor in peripheral blood mononuclear leucocyte in patients with sepsis or septic shock. Clinical Endocrinology 1995;43(2):197-203. [PUBMED: 7554315]
78. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Critical Care Medicine 2003;31:2332-8. [PUBMED: 14501964]
79. Parrillo JE. Pathogenic mechanisms of septic shock. New England Journal of Medicine 1993;328(20):1471-7.
80. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2008;61:991-6.
81. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
82. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337(8741):582-3.
83. The EPISPESIS group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Medicine 2004;30:580-8. [PUBMED: 14997295]
84. Tsao CM, Ho ST, Chen A, Wang JJ, Li CY, Tsai SK, et al. Low-dose dexamethasone ameliorates circulatory failure and renal dysfunction in conscious rats with endotoxemia. Shock 2004;21::484-91.
85. Vachharajani V, Vital S, Russell J, Scott LK, Granger DN. Glucocorticoids inhibit the cerebral microvascular dysfunction associated with sepsis in obese mice. Microcirculation 2006;13:477-87. [PUBMED: 16864414]
86. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for treating severe sepsis and septic shock. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD002243.pub2]
87. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009;301:2362-75. [PUBMED: 19509383]